Palvella Therapeutics (NASDAQ:PVLA) Sets New 12-Month High – Still a Buy?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) shares hit a new 52-week high on Monday . The company traded as high as $151.36 and last traded at $152.2460, with a volume of 245279 shares changing hands. The stock had previously closed at $148.21.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Chardan Capital reissued a “buy” rating and set a $240.00 target price on shares of Palvella Therapeutics in a research note on Thursday, May 21st. HC Wainwright upped their price objective on Palvella Therapeutics from $255.00 to $270.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Monday. Stephens reissued an “overweight” rating and issued a $220.00 target price on shares of Palvella Therapeutics in a report on Thursday, May 21st. Finally, Wall Street Zen lowered shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $199.53.

Palvella Therapeutics Stock Performance

The stock’s 50-day moving average price is $119.85 and its 200-day moving average price is $111.05. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of -32.83 and a beta of -0.15.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). Analysts anticipate that Palvella Therapeutics, Inc. will post -5.26 earnings per share for the current year.

Insiders Place Their Bets

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $110.73, for a total value of $476,360.46. Following the sale, the chief operating officer owned 2,154 shares of the company’s stock, valued at approximately $238,512.42. This represents a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 17.20% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

Large investors have recently added to or reduced their stakes in the business. Group One Trading LLC increased its holdings in Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after acquiring an additional 200 shares in the last quarter. KBC Group NV acquired a new stake in shares of Palvella Therapeutics in the first quarter valued at approximately $28,000. Price T Rowe Associates Inc. MD grew its position in shares of Palvella Therapeutics by 11.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,090 shares of the company’s stock valued at $429,000 after purchasing an additional 433 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Palvella Therapeutics by 12.3% during the 3rd quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock worth $294,000 after purchasing an additional 515 shares in the last quarter. Finally, Deutsche Bank AG raised its position in shares of Palvella Therapeutics by 8.7% during the 4th quarter. Deutsche Bank AG now owns 6,594 shares of the company’s stock worth $690,000 after purchasing an additional 528 shares during the last quarter. 40.11% of the stock is owned by institutional investors and hedge funds.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.